thyroid gland undifferentiated (anaplastic) carcinoma
thyroid gland undifferentiated (anaplastic) carcinoma
Explore linked clinical trials. Standard reference: MONDO:000646826 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Phase 2 | 2026-10-08 | NCT04675710 | |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma | Carcinoma, Medullary, Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor, thyroid gland undifferentiated (anaplastic) carcinoma | Not yet recruiting | Phase 2 | 2026-10-07 | NCT07863765 | |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Recruiting | Phase 1 | 2026-10-05 | NCT06902376 | |
| Sacituzumab govitEcan in THYroid Cancers | Neoplasms by Histologic Type, carcinoma, differentiated thyroid carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Phase 2 | 2026-09-16 | NCT06235216 | |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Phase 1 | 2026-09-10 | NCT05557045 | |
| Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, differentiated thyroid carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 1 | 2026-09-02 | NCT07485569 | |
| Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Recruiting | Phase 2 | 2026-08-20 | NCT07777536 | |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. | Adnexal Diseases, Blood Protein Disorders, Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Erdheim-Chester disease, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Non-Melanoma Skin Neoplasms, Otorhinolaryngologic Neoplasms, Thoracic Neoplasms, Thyroid Cancer, Papillary, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, cancer, carcinoma, cardiovascular disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, glioma, gonadal disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, interstitial lung disease, intestinal disorder, laryngeal disorder, laryngeal neoplasm, lung disorder, lung neoplasm, lymphatic system disorder, lymphoproliferative syndrome, malignant endocrine neoplasm, monoclonal gammopathy, neoplasm, neuroepithelial neoplasm, non-Langerhans cell histiocytosis, non-small cell lung carcinoma, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, pancreas disorder, papillary adenocarcinoma, plasma cell neoplasm, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 / Phase 3 | 2026-08-17 | NCT07440290 | |
| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-08-10 | NCT04171622 | |
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Not yet recruiting | Phase 2 | 2026-07-29 | NCT07470489 | |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, biliary tract disorder, breast disorder, breast neoplasm, carcinoma, cholangiocarcinoma, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastrointestinal stromal tumor, glioma, gonadal disorder, hepatocellular carcinoma, liver disorder, malignant endocrine neoplasm, neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, skin disorder, thyroid gland undifferentiated (anaplastic) carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Recruiting | Phase 2 | 2026-07-27 | NCT05503797 | |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-24 | NCT03181100 | |
| Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Early phase 1 | 2026-07-07 | NCT03085056 | |
| Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-06 | NCT04238624 | |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers | Female Urogenital Diseases and Pregnancy Complications, Gestational Trophoblastic Disease, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pregnancy Complications, Neoplastic, Thoracic Neoplasms, Thymus Neoplasms, Urogenital Diseases, adenocarcinoma, carcinoid tumor, carcinoma, digestive system neuroendocrine neoplasm, epithelial neoplasm, gestational trophoblastic neoplasm, lymphatic system disorder, mixed neoplasm, neoplasm, neuroendocrine neoplasm, peritoneal mesothelioma, pregnancy disorder, primitive neuroectodermal tumor, thymoma, thyroid gland undifferentiated (anaplastic) carcinoma, trophoblastic neoplasm | Active, not recruiting | Phase 2 | 2026-06-25 | NCT06790706 | |
| Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, poorly differentiated thyroid gland carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Not applicable | 2026-06-01 | NCT07068542 | |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, bone disorder, bone giant cell tumor, bone sarcoma, breast disorder, breast neoplasm, carcinoma, connective tissue neoplasm, dedifferentiated chondrosarcoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, giant cell tumor, gonadal disorder, histiocytoma, malignancy in giant cell tumor of bone, malignant endocrine neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, ovarian cancer, ovarian carcinosarcoma, ovarian disorder, poorly differentiated thyroid gland carcinoma, sarcoma, skin disorder, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, triple-negative breast carcinoma, undifferentiated high grade pleomorphic sarcoma of bone, undifferentiated pleomorphic sarcoma | Active, not recruiting | Phase 2 | 2026-05-22 | NCT03449108 | |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Carcinoma, Medullary, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, medullary thyroid gland carcinoma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, primitive neuroectodermal tumor, thyroid cancer, thyroid gland disorder, thyroid gland papillary carcinoma, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-05-20 | NCT04759911 | |
| Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Phase 2 | 2026-04-09 | NCT05696548 | |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Phase 1 | 2026-04-08 | NCT03975231 | |
| [177Lu]Lu-AKIR001 First-in-human Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervical carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, poorly differentiated thyroid gland carcinoma, respiratory system disorder, respiratory tract neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma, uterine disorder, vulva cancer, vulvar disease | Recruiting | Early phase 1 | 2026-01-30 | NCT06639191 | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | Adnexal Diseases, Blood Protein Disorders, Digestive System Diseases, Digestive System Neoplasms, Erdheim-Chester disease, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Thyroid Cancer, Papillary, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cardiovascular disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, glioma, gonadal disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, intestinal disorder, laryngeal disorder, laryngeal neoplasm, lung disorder, lung neoplasm, lymphatic system disorder, lymphoproliferative syndrome, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, monoclonal gammopathy, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, non-Langerhans cell histiocytosis, non-small cell lung carcinoma, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, papillary adenocarcinoma, plasma cell neoplasm, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 / Phase 3 | 2025-11-24 | NCT05768178 | |
| Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Phase 2 | 2025-09-05 | NCT06374602 | |
| Taiwanese Anaplastic Thyroid Cancer Registry | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Not yet recruiting | Not stated | 2025-08-22 | NCT07138261 | |
| Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | Disease Attributes, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Phase 1 | 2025-03-30 | NCT04420754 |